Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Synthekine
National Cancer Institute (NCI)
BeOne Medicines
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Gilead Sciences
BioNTech SE
Bristol-Myers Squibb
AbbVie
Hoffmann-La Roche
Seagen Inc.
Gilead Sciences
Genmab
Merck Sharp & Dohme LLC
PrECOG, LLC.
Hunan Province Tumor Hospital
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Boehringer Ingelheim
QuantumLeap Healthcare Collaborative
Eastern Cooperative Oncology Group
AstraZeneca